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Abstract
Severe infections and their attributable mortality are major complications in recipients of allogeneic hematopoietic stem cell
transplantation (alloSCT). We herein report 236 adult patients who received haploSCT with PTCy. The median follow-up
for survivors was 37 months. The overall incidence of bloodstream infections by gram-positive and gram-negative bacteria
at 37 months was 51% and 46%, respectively. The incidence of cytomegalovirus infection was 69%, while Epstein Barr
virus infections occurred in 10% of patients and hemorrhagic cystitis in 35% of cases. Invasive fungal infections occurred in
11% at 17 months. The 3-year incidence of infection-related mortality was 19%. The median interval from transplant to IRM
was 3 months (range 1–30), 53% of IRM occurred >100 days post-haploSCT. Risk factors for IRM included age >50 years,
lymphoid malignancy, and developing grade III-IV acute GvHD. Bacterial infections were the most common causes of IRM
(51%), mainly due to gram-negative bacilli BSI. In conclusion, severe infections are the most common causes of NRM after
haploSCT with PTCy, with a reemergence of gram-negative bacilli as the most lethal pathogens. More studies focusing on
the severe infections after haploSCT with PTCy and differences with other types of alloSCT in adults are clearly warranted.
Introduction
Over the last decade, several haploidentical hematopoietic
stem cell transplantation (haploSCT) strategies have been
developed to overcome HLA barriers [1–4], improving the
high incidence of graft rejection and graft versus host dis-
ease associated with earlier haploSCT experiences. Cur-
rently, haploSCT has become a real alternative for patients
lacking identical donor, mostly after the introduction of
post-transplant cyclophosphamide [5–11].
Bloodstream infections (BSI) are the most common severe
infections and are a major cause of mortality in patients
undergoing allogeneic hematopoietic stem cell transplantation
(alloSCT) [12], with an incidence ranging from 13 to 46%
[13]. Many risk factors for BSI and severe infectious com-
plications exist, such as prolonged severe neutropenia, mye-
loablative conditioning regimens, severe mucosal damage,
use of broad-spectrum antibiotics; acute graft versus host
disease, prolonged corticosteroids, and previous infectious
history [13–16]. Moreover, delayed immune recovery, as seen
with ex-vivo T cell-depleted alloSCT leads to high incidence
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of late infections in the haploSCT setting, as reported with the
Perugia platforms [1, 17].
Post-transplant cyclophosphamide (PTCy) was a major
milestone in the haploSCT setting. PTCy removes selec-
tively alloreactive donor T cells that are proliferating in
response to host alloantigen while preserving non-
alloreactive donor T cells [18], with surprisingly fast
quantitative immune reconstitution [4, 19]. Despite initial
encouraging results with PTCy [20], infection-related
mortality (IRM) is still the most common cause of mortal-
ity, and possibly higher than in alloSCT from HLA identical
sibling donor (21% vs. 13%, p= 0.002) [11]. Likewise,
IRM was higher in haploSCT without PTCy than a matched
cohort of recipients of HLA identical sibling alloSCT (26+
6% vs. 10+ 4%, p= 0.04) [21].
Currently, despite several advances that have improved
the outcomes after alloSCT, infectious complications remain
a significant problem and a major cause of transplant failure.
In the present study, we describe the incidence of
infections and causative pathogens in different post-SCT
periods (pre-engraftment [<31 days] (PE), early post-
engraftment [31–100 days] and late post-engraftment
[>100 days]), the IRM and causative pathogens, as well
as the overall transplant outcomes, in a large retrospective




Two-hundred thirty-six adult consecutive patients were
transplanted between November 2013 and November 2018
in six centers of the Spanish transplant group (Grupo
Español de Transplante Hematopoyético [GETH]). All
patients received a haploSCT using PTCy as GvHD pro-
phylaxis [16] followed by calcineurin inhibitors, with or
without mycophenolate mofetil (MMF). Transplants were
done according to the local institutional protocols, and all
patients signed informed consent. As a general rule,
exclusion criteria were a poor performance status (ECOG ≥
3 or Karnofsky score <60%), HIV infection, impaired car-
diac or pulmonary functions, active viral hepatitis, and renal
failure (creatinine > x 1.5 ULN). The information was
evaluated retrospectively for each patient.
Conditioning regimens, Gvhd prophylaxis,
and stem cell source
The conditioning regimens were selected by each institution
according to patients’ characteristics and local protocols.
Myeloablative conditioning (MAC) regimens were fludar-
abine (40 mg/m2 IV) from day −6 to −3 and busulphan
(3.2 mg/kg IV) from day −6 to −3 (FluBu4) [22]; or
thiotepa (5 mg/kg IV) on days −7 and −6, fludarabine (50
mg/m2 IV) on days −5, −4, and −3 and busulphan (1 mg/
kg/6 h on days −5, −4, and −3 oral dose, or 3.2 mg/kg/day
IV dose on the same days) (TBF) [23].
Reduced-intensity conditioning regimens (RIC) con-
sisted of fludarabine (30 mg/m2 IV) from day −6 to −2,
cyclophosphamide (14.5 mg/kg IV) on days −6 and −5 and
busulphan (3.2 mg/kg IV) on days −4 and −3 (FluCyBu2).
If the TBF platform was used as RIC, busulphan was
reduced from three to 2 days (days −5 and −4).
All patients received PTCy (50 mg/kg IV on days +3
and +4) as GvHD prophylaxis followed by cyclosporine
combined with MMF or tacrolimus alone since day +5
[22, 23]. Intravenous MESNA was given at a dose of 10
mg/kg/6 h on days +3 and +4 (total daily dose of 40 mg/
kg) as hemorrhagic cystitis (HC) prevention.
Each institution chose to use either peripheral blood (PB)
or bone marrow (BM) as the stem cell (SC) source. The
target dose of CD34+ cells/kg of recipient weight to be
infused was 5 × 106/kg (range 4–6 × 106/kg) in recipients of
PBSC transplantation (PBSCT), while the target dose total
nucleated cells (TNC)/kg recipient weight in BM recipients
was 3 × 108/kg.
The centers selected the haploidentical donor based on
availability and their preference among the first-degree
relatives. Donor-specific anti-HLA antibodies (DSA) were
studied in all patients; a local protocol of desensitisation
was in place in case of inevitable high DSA titers were
found (details not shown).
Definitions and supportive care
The definitions used in the current study are also shown in
detail in the Supplementary online material.
In general, any bacterial, viral, or invasive fungal infection
(IFI) requiring intravenous treatment or hospitalization was
considered a severe infectious episode. In the case of common
bacterial skin contaminants (mostly coagulase-negative sta-
phylococci), a bloodstream infection (BSI) was diagnosed
only if ≥2 consecutive blood cultures were positive for the
same species. Infection data were collected retrospectively
until the patient’s death or last follow-up, using standardized
definitions of severe infections after SCT based on the most
recent guidelines (https://www.ebmt.org/working-parties/
infectious-diseases-working-party-idwp). Common respira-
tory virus infections and virus-related hemorrhagic cystitis
were also included in the study. Cytomegalovirus (CMV)
infection was defined as the presence of at least 2 consecutive
(within a minimum interval of 48 h) positive results of a
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polymerase chain reaction (PCR) test for CMV in peripheral
blood (PB) with a viral load >1000 IU/mL, while CMV
disease was defined as the demonstration of CMV in biopsy
or autopsy specimens from clinically involved visceral sites
by culture and/or histology or if CMV was detected in sam-
ples from clinically-defined sites of disease. Epstein-Bar virus
(EBV) infection was defined as the presence of at least 2
consecutive (within a minimum interval of 7 days) positive
results of a PCR test for EBV in peripheral blood (PB) with a
viral load >1000 e.g.c./mL, with or without evidence of EBV-
related post-transplant lymphoproliferative disease (EBV-
PTLD). Human herpes virus 6 disease was defined as the
presence of positive PCR test in cerebrospinal fluid in patients
with neurological symptoms (encephalitis), and a positive
intestinal biopsy (colitis).
All patients were nursed in HEPA-filtered rooms. Anti-
microbial prophylaxis was given following institutional
policies, but which can be summarized as follows. Bacterial
prophylaxis consisted of ciprofloxacin or levofloxacin dur-
ing neutropenia or until the start of broad-spectrum anti-
biotics. Antifungal prophylaxis was administered according
to the protocols at each site, with either fluconazole and a
pre-emptive strategy; or a mold-active antifungal agent
(posaconazole, voriconazole or other systemic antifungal
drugs) until engraftment or whenever the patient was given
steroids for the treatment of GVHD. Prophylaxis against
Pneumocystis jirovecci consisted of cotrimoxazole until day
−2 and then was restarted after engraftment. Pentamidine
was used if cotrimoxazole was contraindicated. For pre-
vention of Cytomegalovirus (CMV)-related disease, all
institutions followed a preemptive approach with poly-
merase chain reaction (PCR) monitoring; the treatment
started with positive PCR consisted of ganciclovir or fos-
carnet if severe neutropenia or ganciclovir toxicities. Acy-
clovir was recommended for a minimum of 1-year post-
HSCT or until immunosuppressive therapy was stopped.
Galactomannan testing and CMV PCR analysis were per-
formed twice weekly, and Epstein-Barr virus (EBV) PCR
analysis was performed weekly until day +100, in case of
EBV infection, rituximab was used. Intravenous immu-
noglobulin (IVIG) replacement was recommended when-
ever the total IgG blood level was < 400 mg/dL, especially
if the patient had prior infection by encapsulated bacteria or
were considered to be at high risk of humoral
immunodeficiency-linked opportunistic infections. All cen-
ters started the practice of vaccination after 6th months
unless patients had severe active GvHD or were receiving
IVIG therapy
Statistical analyses
SPSS statistics (IBM SPSS Statistics 21) and R studio
programs (R studio, Boston, MA) were used for statistical
analyses. Overall survival (OS) was defined as the time
from day 0 to date of death by any cause, and progression-
free survival (PFS) was the time from day 0 to disease
progression or death. The Kaplan Meier method was used
for estimating the actuarial PFS and OS, and the log rang
test was used to study the univariate impact of any given
variable on OS and PFS. The cumulative incidence (CI)
estimate with competing risk(s) analysis was used to cal-
culate the incidence of acute and chronic GVHD, non-
relapse mortality (NRM), relapse, and infection-related
mortality (IRM). The competing risk for NRM was relapse,
while for relapse it was NRM. Competing risks for acute
and chronic GvHD were disease relapse and NRM up to
100 days after stem cell infusion for acute GvHD and until
the last follow up for chronic GvHD. Competing risk for
IRM was NRM not due to infection or relapse. Competing
risk of infection during a period of infectious risk was NRM
or relapse during the time period. Gray test was used to
study the impact of any given variable on a CI. We used
landmark studies to find the incidence of infections in dif-
ferent time points, and thus time-dependent variables which
occurred before each landmark point were included as
binary variables. If the patients were alive at every time
point they were categorized in two groups (with or without
infection). Patients who died before the time of any given
landmark point were excluded from the next time point. The
time points: <day 31 (pre-engraftment), between days
31–100 (early post engraftment) and > day 100 (late post-
engraftment) were used for infections by GPB, GNB, and
conventional respiratory virus infection. For CMV and
EBV, hemorrhagic cystitis and fungal infections, the time
points selected were <31 and ≥31 days. COX regression
analysis was used for multivariate analysis with doc-
umentation of proportional hazards over time for each
outcome and covariate analyzed. In addition, variables or
events that occurred post-transplant but before a given
landmark point were analyzed as possible risk factors for
IRM, NRM and relapse in the framework of Cox models as
time-dependent covariates (for instance, occurrence of
aGVHD), switching from absent to present at the moment
of occurrence of each covariate/event.
Results
Patient and donor characteristics
Patient and donor characteristics are shown in Table 1. The
median follow up of survivors was 37 months (range
12–82). The median patient age was 50 years (range
17–71), and 61% were male. Seventy-six patients (32%)
had acute myeloid leukemia (AML), which was the most
common underlying disease, followed by lymphoma in 70
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patients (30%). Twenty-seven patients (11%) had failed a
first alloSCT.
One hundred thirty-five patients (57%) were in early
disease phase at transplant (first and second CR; and post-
induction aplasia), although 79 patients (34%) had a high or
very high refined Disease Risk Index (rDRI) [24]. MAC
regimen was used in 32% of the transplants (75 patients).
One hundred thirty-two donors (56%) were male, and the
most common donors used was a son (26%) or a daughter
(17%). An IgG seropositive CMV donor for a seropositive
patient was the most frequent combination in 112 donor-
patient CMV serostatus (48%), only 23% of patients were
CMV seronegative.
Hematological recovery; acute and chronic GVHD
One hundred ninety-one patients (81%) received PBSC. The
median number of CD34+ in PBSCT was 5.4 × 106/kg (range
1.95–11.42), while the TNC infused in BM recipients was
3.5 × 106/kg (range 0.84–19.6). The CI of neutrophil and
platelet recovery was 94% (95% CI, 91–97%) and 90% (95%
CI, 86–94%), respectively. Six patients (2.5%) had primary
graft failure. Nine patients died early (before day +21) without
engraftment (with a severe infection as primary cause of death),
including 5/27 (19%) previously allotransplanted patients.
Table 1 Patient and donors’ characteristics.
Number of cases 236
Patients’ characteristics N (%)
Median age [range] 50 (17–71)
Age ≥50 years/≥60 years 115 (49%)/57 (24%)
Male and female sex 144 (61%)/92 (39%)





Non-Hodgkin’s lymphoma 39 (17%)
Hodgkin disease 31 (13%)
CLL 8 (3%)
CML or other MPS 12 (5%)
Multiple myeloma 5 (2%)




Complete remission (first and second) 130 (55%)
Third complete remission 16 (7%)
Partial remission 33 (14%)
Stable disease 17 (7%)
Progression or refractory disease 33 (14%)
Induction chemotherapy aplasia 5 (2%)
Primary graft failure 2 (1%)
Refined Disease Risk Index (rDRI)
Low rDRI 29 (12%)
Intermediate rDRI 125 (54%)
High rDRI 72 (31%)
Very High rDRI 7 (3%)
Prior HSCT, num. (%) 77 (33%)





Other (FluCyTBI, FluATG) 5 (2%)
Conditioning intensity
Myeloablative 75 (32%)
Reduced intensity 161 (68%)
Stem cell source
Peripheral blood stem cells 191 (81%)
Bone marrow 45 (19%)
GvHD prophylaxis following PTCy




CD34+ cells infused (×106/kg)
(median, range)




Male and female sex 132 (56%)/104 (44%)
Donor relationship with patient
Mother/Father 13 (6%)/23 (10%)
Son/Daughter 61 (26%)/41 (17%)
Brother/Sister 55 (23%)/39 (16%)
Other donors 4 (2%)
Donor and recipient CMV IgG combination
D+/ R+− 112 (48%)
D−/R+ 69 (29%)
D+/ R− 29 (12%)
D−/R− 25 (11%)
AML acute myeloid MDS Myelodysplastic syndrome, ALL acute
lymphoblastic leukemia, CLL chronic lymphocytic leukemia, CML
chronic myeloid leukemia, MPN myeloproliferative neoplasm, HSCT
hematopoietic stem cell transplantation, AlloSCT allogeneic stem cell
transplantation, FluBu fludarabine-busulfan, FluBuBy fludarabine-
busulfan-cyclophosphamide, TBF thiotepa-fludarabine-busulfan, Flu-
CyTBI fludarabine-cyclophosphamide-total body irradiation, FluATG
fludarabine-ATG, GvHD graft versus host disease, PTCy post-
transplantation cyclophosphamide, MMF mycophenolate mofetil,
CMV cytomegalovirus, D donor, R recipient.
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In the 221 remaining patients, the median time to neu-
trophil (>0.5 × 109/L) and platelet (>20 × 109/L) recovery
was 18 days (range 9–49) and 26 days (range 10–156),
respectively.
The CI of grade II-IV and III-VI acute GvHD at day
+100 was 31% (95% C.I., 25–37%) (79 patients) and 11%
(95% C.I., 7–15%) (30 patients), respectively; 5 patients
died as a consequence of steroid-refractory grade III-IV
acute GvHD.
The CI of limited, moderate, and severe chronic GvHD at
37 months was 16% (95% C.I., 12–22%), 8% (95% C.I.,
5–11%), and 7% (95% C.I., 4–10%), respectively. Four
patients died due to severe chronic GvHD.
Transplant outcomes
The OS at 12 and 37 months was 64% (95% C.I., 61–67%)
and 50% (95% C.I., 46–54%), respectively, and the PFS was
57% (95% C.I., 54–60%) and 47% (95% C.I., 44–50%),
respectively. Several variables had an independent impact on
these outcomes in multivariate analysis (MVA); first and sec-
ond CR at transplant, patients ≤ 50 years and grade III-IV acute
GvHD for OS; and first and second CR at transplant, rDRI and
patient age ≤ 50 years for PFS [Table 2].
The CI incidence of relapse at 12 and 37 months was
17% (95% CI, 12–22%) and 21% (95% CI, 16–26%),
respectively. Variables that impacted on relapse in MVA
were the disease response at transplant (first and second CR
vs. other responses) and low-intermediate rDRI [Table 2].
Forty patients (17%) died owing to relapse.
The CI of non-relapse mortality (NRM) was 26% (95%
CI, 21–31%) and 31% (95% CI, 25–37%) at 12 and
37 months. Prior alloSCT, age ≥50 years and grade III–IV
acute GVHD were risk factors in the MVA [Table 2]. The
main cause of NRM was an IRM (58% of NRM, 43
patients) [Table 3].
Infection-related mortality and severe infectious
complications
The CI of IRM at 12 months was 17% (95% C.I., 12–22%)
and 19% (95% C.I., 14–24%) at 37 months, and the vari-
ables with an independent impact in the MVA analysis were
age ≥ 50 years, lymphoid malignancy as underlying disease
(vs. myeloid), and development of grade III-IV acute GvHD
[Table 2].
Six hundred twenty-three severe infectious episodes
were reported in the 236 patients, with 2.6 infections per
patient (range 0–8). Only 17 patients (7%) did not develop
any severe infections. In addition, 14% (32 patients)
developed a clinically defined severe infection without
microbiological documentation, and 10% required ICU
admission due to a severe infection.
Fifty-six percent of patients developed at least one
bacterial infection (19% of patients had gram-positive
bacterial infections, 15% had gram-negative bacterial
infections, and 22% had both types of bacterial infections).
CMV infection (CMV-I) was found in 69% of patients,
and 52% had at least one non-CMV viral infection. An
invasive fungal infection (IFI) occurred in 41 patients
(17%), including 10% of possible, probable, or proven
invasive aspergillosis. Specific pathogens involved, their
distribution post-transplant, and the median time to onset
of the major types of infections per time period are shown
in detail in Table 4.
There were 43 cases of IRM; the median interval from
transplant to IRM was 3 months (range 10–927); eight (19%)
died during the PE period, 12 patients (28%) developed a lethal
infectious complication in the early post-engraftment period,
and 23 patients (53%) died beyond +100 days. In 51% (22
patients), the cause of IRM was bacterial, 16% (7 patients)
developed a lethal viral infection, 5% (2 patients) an IFI, and
two patients had a mixed bacterial and fungal infection. In 23%
of clinically documented IRM no microbiological doc-
umentation was reported. The documented primary causes of
IRM and NRM are shown in Table 3.
All IS was discontinued in 161 of patients (68%) at a
median time post-transplant of 199 days (range 1–37 months),
and seven of these patients died as a consequence of infection
(4.3% IRM). Six of these seven patients died after day +100.
In 75 patients (32%) discontinuation of IS therapy had
not been possible at last follow-up. Thirty-three patients
died before 100 days, and the main causes of death were
infection (19 patients, 25% IRM), while of the 42 patients
who received IS drug/s after day +100, 17 died due to
infections (40% IRM) and 12 patients were still alive at last
follow-up more than 1 year post-transplant.
Bacterial infections
The incidence of PE ( < day +31), early post-engraftment
(day +31 to +100) and late post-engraftment (> day +100)
infections by gram-positive bacteria (GPB) was 20% (95%
C.I., 15–25%), 11% (95% C.I., 7–15%) and 20% (95% C.I.,
14–26%), respectively, with an overall incidence of
51%. The median time of infection was 10 days (range
0–28), 72 days (range 32–97), and 7 months (range 3–29),
respectively.
One hundred twenty-two infection episodes by GPB
were reported (shown in detail in Table 4) of which 46%
(56 episodes) occurred in the PE period. Staphylococcus
spp. and Enterococcus spp. were the most frequent
GPB. Six of seven patients with Streptococcus spp. infec-
tion in the late post-engraftment period were caused by
Streptococcus pneumoniae. Only eight GPB (6%) presented
antibiotic resistance (Methicillin-resistant Staphylococcus
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Causes of IRM N 43 (58%) 8 (19) 12 (28) 23 (53)
Gram positive bacterial (N 7) 2 3 2
Enterococcus faecium 2






Gram negative bacterial (N 13) 2 2 9
Escherichia coli 1












Viral infection (N 7) 1 3 3
CMV disease (pneumonitis) 1 2 1
Metapneumovirus 1
Human herpes 6 virus 1
EBV-PTLD 1
Invasive fungal infection (N 2) 1 1
Probable IFI 1 1
Gram negative bacterial+
fungal infection (N 2)
1 1






Other causes of NRM N 26
(35%)
4 (15) 9 (35) 13 (50)
Graft rejection 1 2 2
Sinusoidal obstruction syndrome 2 1
Idiophatic encephalitis 2 1
Refractory acute GvHD 2 3
Chronic GvHD 4
Other NRM causes 1 2 3
Secondary neoplasms N 5 (7%) 5
Other NRM causes: non-infectious endocarditis (x1), adult respiratory distress syndrome (x1), refractory bleeding (x1), alveolar refractory bleeding
(x2) and sudden death (x1).
NRM non relapse mortality, IRM infection-related mortality, ESBL extended-spectrum beta-lactamase, CMV cytomegalovirus, PT-LPD post-
transplant lymphoproliferative disorder, EBV Epstein-Barr virus, IFI invasive fungal infection, PTLD post-transplant lymphoproliferative disease.
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Total infectious episodes N= 623
(100%)
205 (33) 214 (34) 204 (33)
Gram positive bacteria N= 122
(20%)
56 (46) 25 (20) 41 (34)
Median time of GPB infections
days or months (range)
10 days (0–28) 72 days (32–97) 7 months (3–29)
Staphylococcus spp 31 13 22
Enterococcus spp 17 10 10
Streptococcus spp 5 7
Corynebacterium spp 2
Bacillus spp 1
Listeria monocytogenes 2 1
Nocardia spp 1
Gram N= egative bacterial
N= 107 (17%)
23 (21) 34 (32) 50 (47)
Median time of GNB infections
days or months (range)
13 days (0–28) 51 days (35–97) 7 months (3–33)
Escherichia coli 10 8 17
Pseudomonas aeruginosa 7 10 14
Klebsiella pneumoniae 2 7 8
Stenotrophomonas maltophilia 3 1 3
Serratia marcescens 1 2 1





Clostridium difficile N= 17 (3%) 10 (59) 5 (29) 2 (12)
Median time of CD infection days
or months (range)
5 days (2–20) 42 days (32–47) –
Viral infections
Cytomegalovirus N= 155 (25%) 58 (38) 84 (54) 13 (8)
Median time of CMV infections
days or months (range)
21 days (0–30) 42 days (31–100) 5 months (3–31)
Reactivation 54 84 12
Disease 4 – 1
Epstein–Barr Virus N= 23 (4%) 5 (22) 18 (72)
Median time of EBV infections
days or months (range)
– 85 days (69–98) 5 months (3–20)
Reactivation – 5 16
EBV-PTLD 2
Hemorrhagic cystitis N= 77
(12%)
32 (42) 37 (48) 8 (10)
Median time of HC infection days
or months (range)
14 days (0–30) 45 days (31–98) 4 months (3–7)
BK Poliomavirus-related 20 31 3
Adenovirus 1 3 1
Without viral infection 11 3 4
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aureus (MRSA) and MR S. epidermidis, with 4 infections
each). All GPB infections were BSI except for 3 cases of
listeriosis and one case of nocardiosis.
There were 7 cases of IRM caused by GPB infections
(16% of IRM), two infections before +30 days due to
Enterococcus faecium, three in the post-engraftment period
caused by Streptococcus mitis, Enterococcus faecalis, and
MRSA and two late infections (> +100 days) due to
Enterococcus faecalis and Streptococcus pneumoniae








Upper respiratory tract viral
infections N= 34 (5%)
2 (6) 10 (29) 22 (65)
Median time of URT infections
days or months (range)
– 70 days (63–84) 10 months (4–42)
Influenza virus 5 10
Respiratory syncytial virus 5 2
Parainfluenza virus 1 6
Rhinovirus 1 2
Adenovirus 2
Lower respiratory tract viral
infections N= 28 (4%)
5 (18) 3 (11) 20 (71)
Median time of LRT infections
days or months (range)
17 days (19–22) – 7 months (3–37)
Respiratory syncytial virus 2 8
Influenza virus 1 1 6




Other viral infections N= 19
(3%)
5 (26) 5 (26) 9 (48)
Median time of other virus
infections days or months (range)
15 days (5–21) 63 days (40–93) 5,5 months (3–12)
Human herpes type 6 virus 1 3 3
Adenovirus 3 1
Rotavirus 2
Herpes simplex virus 2
Hepes zoster virus 2
Enterovirus 1
Norovirus 1
Invasive fungal infections N= 41
(7%)
14 (34) 13 (32) 14 (34)
Median time of fungal infections
days or months (range)
10 days (0–28) 72 day (31–99) 11 months (4–46)
Possible IA 2 2 2
Probable IA 5 1 2
Proven IA 1 3 4





GPB gram positive bacteria, GNB gram negative bacteria, CD clostridium difficile, CMV cytomegalovirus, EBV-PTLD EBV-related Post-
transplant lymphoproliferative disease, HC Hemorrhagic cystitis, URT upper respirtory tract, LRT lower respiratory tract, IA invasive aspergillosis.
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With respect to infections by gram-negative bacteria
(GNB), the incidence of PE ( < day +31), early post-
engraftment (day +31 to +100) and late post-engraftment
(> day +100) infections was 10% (95% C.I., 6–14%), 14%
(95% C.I., 9–19%) and 22% (95% C.I., 16–28%), respec-
tively, with an overall incidence of 46%. The median time
of infection was 13 days (range 0–28), 51 days (range
35–97), and 7 months (range 3–33). Details are shown in
Table 4. One hundred seven GNB infections occurred, all
were BSI, and as apposed to GPB infections the highest rate
of GNB infections occurred in the late post-engraftment
period risk, with 50 episodes (47%) of GNB infections. The
most common pathogens isolated were Escherichia coli,
Pseudomonas aeruginosa, and Klebsiella pneumoniae,
which accounted for 83/107 (78%) of GNB infections
among these three species, 16% were antibiotic-resistant
(eight multidrug-resistant (MDR) Pseudomonas aerugi-
nosa, three extended-spectrum beta-lactamase producing
(ESBL) Escherichia Coli and seven ESBL or carbapena-
mase producing Klebsiella pneumoniae). Other innately
MDR species included 7 infections by Stenotrophomonas
maltophila and one case of Acinetobacter baumanii.
The causes of IRM by GNB are shown in detail in
Table 3, which accounted for 30% of IRM (13 patients);
two lethal infections in the PE period (MDR Pseudomonas
aeruginosa and ESBL Escherichia coli), two in the early
post-engraftment period (MDR Pseudomonas aeruginosa,
and ESBL Klebsiella pneumonia), and 9 patients in the late
post-engraftment period (one Pseudomonas aeruginosa and
one MDR Pseudomonas aeruginosa; one ESBL Klebsiella
pneumoniae and two Klebsiella pneumoniae, one Escher-
ichia coli, one Serratia marcescense, Stenotrophomona
maltophilia and Acinetobacter baumannii).
Virus infections
CMV and EBV Infections
The incidence of CMV infection (CMV-I) in PE period
(< day +31) and post-engraftment period (≥31 days) was 25%
(95% CI, 20–30%) and 44% (95% CI, 38–50%), respectively.
In three patients were showed the CMV infection after
12 months. Among CMV seropositive patients the incidence
of CMV-I was 78% (95% C.I., 72–84%), whereas it was 24%
(95% C.I., 12–36%) in seronegative recipients. Five patients
developed CMV pneumonitis, in four cases before day +31
and one on day +155, and four died from this complication.
The incidence of EBV reactivation was 10% (95% CI,
6–14%), mainly in the late post-engraftment period (18/23
cases). Fifteen patients were treated with rituximab due to
high EBV DNAemia (>1000 e.g.c./mL). EBV-related post-
transplant lymphoproliferative disorder (EBV-PTLD) was
diagnosed in two patients and was lethal in one of these cases.
Community/conventional respiratory virus (CRV) infections
Sixty-two episodes of CRV infections were reported, and the
incidence of at least one episode of CRV infection was 4%
(95% C.I., 1–7%) in the PE period, 5% (95% C.I., 2–8%) in
the early post-engraftment and 15% (95% C.I., 10–20%) in the
late post-engraftment period. Only one patient died as a con-
sequence of metapneumovirus pneumonia.
Upper (URTI) and lower (LRTI) respiratory tract infections
by a CRV accounted for 34 and 28 episodes (55% and 45%),
respectively (details shown in Table 4). Both URTI and LRTI
occurred mostly in the late post-engraftment period (65 and
71% of CRV infections, respectively). The most CRV in URTI
were influenza viruses (14 episodes), respiratory sincytial virus
(7 episodes) and parainfluenza viruses (7 episodes), whereas
respiratory sincytial virus (10 episodes) and influenza viruses (6
episodes) were the most common in LRTI.
Other viral infections
A very frequent complication in haploSCT protocols with
PTCy is hemorrhagic cystitis (HC), as confirmed in the current
study. The incidence of HC until +30 days was 14% (95% C.
I., 10–18%) and after day +31 it was 21% (95% C.I.,
16–26%), for an overall incidence of 35%. BK-polyomavirus-
related HC was diagnosed in 54 cases (70% of HC), while
adenovirus-related HC was found in five cases (6% of HC). No
viral pathogen was identified in 18/77 cases of HC (23%), 11
of which occurred early post-transplant.
Human Herpes virus type 6 infection was diagnosed in 7
patients, with two cases of encephalitis and 5 cases of
colitis. Other less common cutaneous and intestinal viral
infections are shown in Table 4.
Invasive fungal infections
The incidence of invasive fungal infections (IFI) was 4%
(95% C.I., 3–5%) before +31 days and 7% (95% C.I.,
4–10%) after day +31, for a 3-year incidence of 11%. The
most common IFI was invasive aspergillosis (IA), with eight
cases of proven IA, eight probable IA and six cases of pos-
sible IA. An IFI was the primary cause of death for two
patients with proven IA and one probable IA. Pneumocystis
jirovecci pneumonia was diagnosed in the late post engraft-
ment period in only two patients, while uncomplicated can-
didemia occurred in 16 patients (7%) [details in Table 4].
Discussion
In the current study, we describe the incidence of severe
infections and the IRM in a large series of adult recipients of
a haploSCT with PTCy. As previously described in other
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studies infectious complications are the main cause of
NRM, as occurs with other types of alloSCT [25, 26]. The
3-year incidence of NRM was 31% and 19% for IRM in the
present study.
In our series, the 3-year incidence of GPB and GNB
infections was 51% and 46%, respectively (246 episodes),
similar to the incidence reported by others which range
from 35% to 62% [27–30], albeit somewhat different
definitions were used in different studies. The rates of
GPB infections were similar in the pre-engraftment and
late post-engraftment period, while GNB infections were
more common in the late post-engraftment period (> day
+100). Risk factors for these late GNB infections have
been reported, although we did not analyze their risk
factors due to the large number of species involved
and thus small numbers per pathogen [14]. Bacterial
infections were the most common causes of IRM (51%,
22 patients), mainly GNB infections (30%, 13 patients).
As expected, Escherichia coli, Pseudomonas aeruginosa,
and Klebsiella pneumoniae were the most common GNB
species [14, 27, 29, 31].
Antibiotic resistance appeared to contribute to IRM. A
MDR strain was involved in 6/13 (46%) deaths by GNB,
while only 16/83 (19%) overall isolated were MDR, and
three additional patients died due to Acinetobacter bau-
mannii, Serratia marcescens, and Stenotrophomonas
maltophilia. Knowledge of the epidemiology of MDR
GNB in each hospital as well as prior infections by these
pathogens in any given patient is crucial in establishing
the best empirical antibiotic strategy [14, 32, 33]. On the
other hand, a high incidence of GPB was found during the
study; however, antibiotic resistance was rare among GPB
(6%), and only one patient died due to MRSA infection.
Regarding CMV-I, a high incidence was found in our
series (24% during PE period and 45% beyond ≥31 days), in
contrast to a low rate of CMV disease (2%), as reported by
others [27, 29, 34–36]. A higher incidence of CMV-I in
haploSCT with PTCy compared with other donor types has
been reported previously [27, 36–38]. Initial studies hypo-
thesized that the high incidence of CMV-I correlated with
delayed CD4+ T cell and dendritic cell recovery [39, 40].
Also, CMV-I has a strong impact on the integrity and het-
erogeneity of the T cell repertoire, leading to CD8+ effector
memory T cell expansion and contraction of naïve cells [41].
However, a recent report found that CMV-specific-T-cell
reconstitution in T-cell replete haploSCT with PTCy was
comparable to other types of alloSCT without PTCy [42].
More studies are necessary to define the relationship between
CMV-I and immunological reconstitution.
Interestingly, we found a low incidence of EBV-I (10%)
and EBV-PTLD (2 patients), as recently reported by other
groups [27, 43]. The immunological hypothesis for the low
incidence of EBV-I and EBV-PTLD is unclear, but the lack
of in vivo or ex vivo T-cell depletion is of course a major
determinant for the low incidence [42].
In haploSCT with PTCy the incidence of HC has been
reported to range from 19% to 60% [38, 44]. Recent pub-
lications showed a higher incidence of HC in haploSCT
with PTCy than in alloSCT from matched related donors
also with PTCy (55% vs. 25%) [44, 45], suggesting that the
use of PTCy is not the main risk factor for the higher
incidence of HC in haploSCT. As expected, BK Poly-
omavirus was the most common virus linked to HC (70% of
cases) in our series. In the haploSCT setting donor T lym-
phocytes are HLA mismatched with urothelial viral antigen-
presenting cells, compromising the immune effector T cell
response [45]. Although there is no treatment nor prophy-
laxis for viral-related HC, the continuous intravenous
infusion of MESNA has been recently reported to reduce
the incidence of HC when compared with bolus adminis-
tration (5.6% vs. 27.8%) [46], although this requires con-
firmation with further studies.
A low incidence of IFI was found (11% at 3 years),
especially during the early aplastic post-transplant period
(4%) and with a very low impact on IRM. Due to the low
incidence, we were unable to analyze the risk factors for
developing an IFI.
Among the patients on immunosuppressive drugs (IS)
during the entire study follow-up, 40% of all IRM (17
patients) occurred in patients after +100 days and 44% of
all IRM occurred before day +100 (19 patients). However,
in the 161 patients who discontinued IS post-transplant the
IRM was low (7 patients, 4.3% rate of and 16% of all the
cases of IRM).
The present study shares the limitations inherent to ret-
rospective studies, including potential selection bias; and
the uncertainty of whether all infections were captured and
included in the study. However, the study gives a useful
picture of the overall epidemiology of different severe
infections and their impact on IRM in the setting of adult
haploSCT with PTCy in our country.
In conclusion, our national study shows that IRM is the
main cause of NRM in the haploSCT setting with PT-Cy. A
major cause of IRM were GNB infections, possibly higher
in patients with MDR GNB infections. Studies focusing on
the immunological reconstitution, especially in patients
without severe GVHD, may help in understanding the high
incidence of late infections linked to cellular immunity,
such as CMV and viral-related HC.
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